Rational Design of Broad Spectrum Antibacterial Activity Based on a Clinically Relevant Enoyl-Acyl Carrier Protein (Acp) Reductase Inhibitor.
Schiebel, J., Chang, A., Shah, S., Lu, Y., Liu, L., Pan, P., Hirschbeck, M.W., Tareilus, M., Eltschkner, S., Yu, W., Cummings, J.E., Knudson, S.E., Bommineni, G.R., Walker, S.G., Slayden, R.A., Sotriffer, C.A., Tonge, P.J., Kisker, C.(2014) J Biol Chem 289: 15987
- PubMed: 24739388 
- DOI: 10.1074/jbc.M113.532804
- Primary Citation of Related Structures:  
4CUZ, 4CV0, 4CV1, 4CV2, 4CV3, 4BKU - PubMed Abstract: 
Determining the molecular basis for target selectivity is of particular importance in drug discovery. The ideal antibiotic should be active against a broad spectrum of pathogenic organisms with a minimal effect on human targets. CG400549, a Staphylococcus-specific 2-pyridone compound that inhibits the enoyl-acyl carrier protein reductase (FabI), has recently been shown to possess human efficacy for the treatment of methicillin-resistant Staphylococcus aureus infections, which constitute a serious threat to human health ...